All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On November 4, 2020, results were announced from a phase I trial evaluating actimab-A in combination with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML). Of the evaluable patients in the third and planned final dose cohort, 100% achieved remission.1
Actimab-A is an antibody–drug conjugate comprising the CD33-targeting monoclonal antibody, lintuzumab, and actinium-225. The agent was designed to selectively deliver actinium-225 to cancer cells, resulting in double-stranded DNA breaks and cell death.2
The actimab-A + CLAG-M combination regimen is being evaluated in patients aged ≥ 18 years who are deemed fit for cytotoxic chemotherapy. This phase I trial was preceded by the Investigational New Drug application clearance by the U.S. Food and Drug Administration (FDA) in 2018.
The novel combination was administered across three cohorts (N = 15) receiving distinct doses of actimab-A (0.25, 0.50, and 0.75 uCi/kg) with the standard regimen of CLAG-M. Across the treatment cohorts, 67% of patients achieved a complete remission (CR) or CR with inadequate hematopoietic recovery (CRi), and 83% of patients who had received ≤ 3 prior lines of therapy achieved CR or CRi. Of the patients achieving CR/CRi, 70% were measurable residual disease (MRD) negative. Data from all three cohorts, including those employing subtherapeutic doses of actimab-A, indicate the superiority of the combination over CLAG-M alone (overall response rate: 55%; MRD negativity: 39%). In the 0.75 uCi/kg actimab-A dose cohort, 100% of evaluable patients (n = 3) achieved CR/CRi.1
The planned final dose of actimab-A (0.75 uCi/kg) in combination with CLAG-M demonstrated a clinically acceptable safety profile. As a result, patients are currently being screened and enrolled to evaluate a fourth dose of 1.0 uCi/kg actimab-A.1
Data from this phase I study will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually on December 5–8, 2020.
Subscribe to get the best content related to AML delivered to your inbox